Casdin Capital, LLC Sage Therapeutics, Inc. Transaction History

Casdin Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $3.66 Million - $5.36 Million	90,000 New	90,000 $4.23 Million
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $9.99 Million - $16.6 Million	-385,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$26.15 - $77.24 $4.05 Million - $12 Million	155,000 Added 67.39%	385,000 $11.1 Million
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $10.2 Million - $26.3 Million	-170,000 Reduced 42.5%	230,000 $16.6 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $7.86 Million - $14.4 Million	88,000 Added 28.21%	400,000 $63.6 Million
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $8.56 Million - $10.5 Million	62,000 Added 24.8%	312,000 $44.1 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $607,200 - $1.67 Million	10,000 Added 4.17%	250,000 $41.2 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $14.7 Million - $21.2 Million	240,000	240,000 $15 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Casdin Capital, LLC with notifications on news.